152 related articles for article (PubMed ID: 20195232)
1. Current immunosuppressive approaches in liver transplantation.
Iacob S; Cicinnati VR; Beckebaum S
Panminerva Med; 2009 Dec; 51(4):215-25. PubMed ID: 20195232
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
3. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
4. The role and value of sirolimus administration in kidney and liver transplantation.
Mehrabi A; Fonouni H; Kashfi A; Schmied BM; Morath Ch; Sadeghi M; Schemmer P; Encke J; Sauer P; Zeier M; Weitz J; Büchler MW; Schmidt J
Clin Transplant; 2006; 20 Suppl 17():30-43. PubMed ID: 17100699
[TBL] [Abstract][Full Text] [Related]
5. Long-term maintenance therapy with calcineurin inhibitors: an update.
Campistol JM
Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
[TBL] [Abstract][Full Text] [Related]
6. Operational tolerance: past lessons and future prospects.
Levitsky J
Liver Transpl; 2011 Mar; 17(3):222-32. PubMed ID: 21384504
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin inhibitors in liver transplantation: to be or not to be.
Castroagudín JF; Molina E; Varo E
Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
[TBL] [Abstract][Full Text] [Related]
8. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
9. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
[TBL] [Abstract][Full Text] [Related]
10. Evidence for immunosuppression in lung transplantation.
Hopkins PM; McNeil K
Curr Opin Organ Transplant; 2008 Oct; 13(5):477-83. PubMed ID: 19060529
[TBL] [Abstract][Full Text] [Related]
11. Everolimus in clinical practice--renal transplantation.
Pascual J
Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
[TBL] [Abstract][Full Text] [Related]
12. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
13. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
14. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
[TBL] [Abstract][Full Text] [Related]
15. Management of posttransplant hepatitis C infection.
Aytaman A; Kaufman M; Terrault NA
Curr Opin Organ Transplant; 2010 Jun; 15(3):301-9. PubMed ID: 20445452
[TBL] [Abstract][Full Text] [Related]
16. Liver transplant: a primer.
Movahedi Z; Holt CD; Saab S
Exp Clin Transplant; 2010 Jun; 8(2):83-90. PubMed ID: 20565363
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation.
Alamo JM; Barrera L; Casado MD; Bernal C; Marin LM; Suarez G; Sanchez-Moreno L; Jimenez R; Suarez-Grau JM; Sousa JM; Cordero E; Gomez-Bravo MA
Transplant Proc; 2009; 41(6):2181-3. PubMed ID: 19715866
[TBL] [Abstract][Full Text] [Related]
18. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
20. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?
Wali RK; Weir MR
Curr Opin Organ Transplant; 2008 Dec; 13(6):614-21. PubMed ID: 19060552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
